There is an interesting line in the Chinese study on remdesivir that has gone almost entirely overlooked, one that introduces an interesting, and potentially serious, conundrum. The authors of the study wrote that “Remdesivir did not result in significant reductions in SARS-CoV-2 RNA loads or detectability in upper respiratory tract or sputum specimens in this study….

In short, what the authors are saying here is that remdesivir—an antiviral drug that is supposed to work by stopping the virus from replicating—did nothing to actually stop the virus from replicating. Patients who received remdesivir had the same viral load as those who didn’t.

Read full article on Forbes

Originally published on Forbes (May 1, 2020)